Alembic Pharmaceuticals

Quick check

The five things to look at first. Open one for more.

• DebtHigh safetyRated AA+ by CRISIL.
• ResultsGrowingIn the Jun 2026 quarter, sales rose 26% and profit rose 12% from a year earlier.
• DilutionNo new sharesNo new shares issued in the last year, so existing shareholders' slices were not cut.
• PromotersSteadyThe promoters (founders or parent) own 70% of the company, about the same as in Jun 2025.
• ValuationCheap vs its pastThe share trades at 20.6 times its yearly earnings (P/E), cheaper than 86% of the time in the last 5 years. Its usual P/E is about 22.

Alembic Pharmaceuticals against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.

• Valuation (P/E)20.6 against a typical 34.3: cheaper than most peers (1st = cheapest).63rd of 220
• Sales growth+25.7% against a typical +15.6% from a year earlier.66th of 197
• Profit growth+11.7% against a typical +18.9% from a year earlier.96th of 160
• Share price, 3 months−2.9% against a typical −0.5%.111th of 200
• Size₹ 14,927.5 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).33rd of 199

Exchange filings and their impact on the company.

• 27 Oct 2026Press ReleaseLow impactPositivePrice +0.1% that day
  Alembic wins USFDA final approval for niche Valganciclovir oral solution, adding a small US sales kicker.

  Alembic Pharmaceuticals received USFDA final approval for its generic Valganciclovir for Oral Solution 50 mg/mL, equivalent to Valcyte oral solution for CMV retinitis and CMV prevention in transplant patients. The company now has 247 cumulative ANDA approvals, with 227 final and 20 tentative. The product is a small niche US generic that should add modest incremental US sales over the next 12 months.

  Full analysisFiling
• 17 Oct 2026Press ReleaseLow impactPositivePrice +0.1% on 19 Oct
  Alembic won USFDA final approval for its $110m Ciprodex generic, adding a small high-margin US sales kicker.

  Alembic Pharmaceuticals received USFDA final approval for its generic Ciprofloxacin and Dexamethasone Otic Suspension 0.3%/0.1%, equivalent to Sandoz's Ciprodex for ear infections. IQVIA pegs the US market at $110 million for the 12 months to June 2026. The approval takes Alembic to 246 total ANDA approvals and should add a small, profitable US product to its portfolio.

  Full analysisFiling

Results dates and other board meetings. Full calendar

Compounded yearly rates over each period.

Listed companies in the same business.

Chirayu R. Amin

Executive Chairman of the Board

G. Krishnan

Chief Financial Officer

Manisha Saraf

Compliance Officer, Company Secretary

Pranav C. Amin

Managing Director, Executive Director

Shaunak Amin

Managing Director, Executive Director